Controversy over the cardiovascular effects of thiazolidinediones.
Kapoor
John R
JR
D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000401:mortality; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis / Q000188:drug therapy; D005500:Follow-Up Studies; D006801:Humans; D006943:Hyperglycemia / Q000175:diagnosis / Q000188:drug therapy*; D007333:Insulin Resistance; D009203:Myocardial Infarction / Q000139:chemically induced / Q000401:mortality; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D000077154:Rosiglitazone; D015996:Survival Rate; D045162:Thiazolidinediones / Q000009:adverse effects* / Q000627:therapeutic use
D045162:Thiazolidinediones; D000077154:Rosiglitazone